MAIA Biotechnology, Inc. (MAIA) - 10-K Summary
Business Context and Reporting Period
Company: MAIA Biotechnology, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: MAIA is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. Its lead asset, ateganosine (THIO), is a telomere-targeting agent designed to be administered sequentially with immune checkpoint inhibitors (CPIs). The company operates primarily in Chicago, Illinois, with subsidiaries in Australia and Romania.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(22,396,172) | $(23,254,656) |
| Operating Expenses | $24,269,686 | $16,957,210 |
| Cash and Cash Equivalents (End of Period) | $8,658,031 | $9,601,298 |
| Working Capital | $3,865,458 | $6,322,441 |
| Accumulated Deficit | $(109,631,005) | $(87,234,833) |
| Stockholders' Equity | $2,375,863 | $3,634,636 |
Note: The company has no commercial revenue and relies on financing activities and grants to fund operations.
Material Changes vs. Prior Period
- Operating Expenses: Increased by 43% (approx. $7.3 million) to $24.3 million, driven by a 45% increase in R&D expenses ($14.5M vs $10.0M) due to clinical trial expansion and a 40% increase in G&A expenses ($9.7M vs $6.9M).
- Net Loss: Decreased slightly by 4% to $22.4 million, primarily due to a $7.9 million gain from the change in fair value of warrant liabilities, offsetting higher operating costs.
- Cash Flow: Net cash used in operating activities increased to $18.8 million (from $15.7 million). Net cash provided by financing activities was $17.9 million, funded by private placements and At-The-Market (ATM) offerings.
- Grant Income: Recognized $361,350 in grant income in 2025, compared to $0 in 2024.
Guidance, Outlook, and Management Commentary
- Clinical Progress:
- THIO-101 (Phase 2): Completed enrollment for the 180mg dose. Expansion arms initiated in July 2025 for third-line NSCLC patients. Updated data (as of June 30, 2025) showed a median Overall Survival (OS) of 17.8 months and median Progression-Free Survival (PFS) of 5.6 months in the third-line setting.
- THIO-104 (Phase 3): Initiated in December 2025 with the first patient dosed. This pivotal trial compares ateganosine + CPI vs. chemotherapy in up to 300 third-line NSCLC patients.
- Regulatory Milestones:
- Received Fast Track Designation from the FDA for NSCLC (July 2025).
- Received Rare Pediatric Disease Designation for pediatric-type diffuse high-grade gliomas (PDHGG) (Dec 2024), potentially qualifying for a Priority Review Voucher.
- Received Orphan Drug Designation for HCC, SCLC, and Malignant Gliomas.
- Strategic Partnerships:
- Regeneron: Supply agreement for cemiplimab (Libtayo) for THIO-101.
- BeOne Medicines (BeiGene): Supply agreement for tislelizumab for trials in HCC, CRC, and SCLC.
- Roche: Master supply agreement for atezolizumab (Tecentriq) for future studies.
- Outlook: Management plans to seek accelerated approval for ateganosine in the U.S. for advanced NSCLC in 2026 based on THIO-101 data. The company also plans to initiate Phase 1 trials for second-generation molecules in 2026.
- Digital Asset Strategy: The company announced a digital asset treasury strategy in October 2025 but placed it on hold due to volatility; holdings were approximately $0 as of the report date.
Key Facts for Investor Verification
- Liquidity Status: As of Dec 31, 2025, cash was $8.7M. However, a subsequent underwritten public offering in March 2026 raised approximately $33 million, resolving substantial doubt about the company's ability to continue as a going concern.
- Capital Structure: Significant dilution occurred in 2025 through multiple private placements and ATM offerings. Outstanding warrants and options remain high (approx. 13M warrants and 12.9M options).
- Intellectual Property: The company relies heavily on license agreements with the University of Texas Southwestern (UTSW). Milestone payments up to $112 million and royalties (2-5%) are contingent on future commercial sales.
- Clinical Risk: The company has no approved products. Success depends entirely on the efficacy and safety of ateganosine in ongoing Phase 2 and Phase 3 trials. Accelerated approval is not guaranteed.
- Competition: Faces competition from established checkpoint inhibitor franchises (e.g., Keytruda, Opdivo) and other telomere-targeting therapies.